BS_TJTEF70D
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 41.06438896189225
- age_years
- 2.685
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.441
- UNFOLDED_PROTEIN_RESPONSE+0.380
- MYC_TARGETS_V1+0.378
- E2F_TARGETS+0.336
- NOTCH_SIGNALING+0.307
- OXIDATIVE_PHOSPHORYLATION+0.291
- DNA_REPAIR+0.290
- G2M_CHECKPOINT+0.266
- HEME_METABOLISM+0.232
- MTORC1_SIGNALING+0.230
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.299
- IL6_JAK_STAT3_SIGNALING-0.290
- ALLOGRAFT_REJECTION-0.268
- TNFA_SIGNALING_VIA_NFKB-0.262
- APICAL_JUNCTION-0.258
- INFLAMMATORY_RESPONSE-0.254
- COAGULATION-0.251
- HYPOXIA-0.237
- CHOLESTEROL_HOMEOSTASIS-0.236
- APICAL_SURFACE-0.217
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | E3E4E7DA-AD14-44BA-B3BE-02652B3CEE18 | — | — | 0.858 |
| 2 | BS_FTKPQ5FZ | Supratentorial Ependymoma | — | 0.855 |
| 3 | BS_7G42J2SK | Supratentorial Ependymoma | — | 0.853 |
| 4 | BS_QXKRN6CR | EPN | Supratentorial EPN | 0.848 |
| 5 | 4D9EF242-9F58-4681-ADCF-556E05932931 | — | — | 0.845 |
| 6 | 6EE50ED0-9F0E-4393-B165-257D5C03F221 | — | — | 0.843 |
| 7 | E79FE058-F03E-45F3-A939-356B0427E1B7 | — | — | 0.840 |
| 8 | SRR934724 | — | — | 0.835 |
| 9 | BS_G63HYD6N | Supratentorial Ependymoma | — | 0.834 |
| 10 | TCGA-A8-A07S-01A-11R-A034-07 | — | B | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.441 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.378 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.336 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.307 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.291 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.266 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.232 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.190 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.182 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.177 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.133 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.118 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.117 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.114 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.103 | Inavolisib | — uncovered |